Category: newsletters

2018 Year In Review: FDA Drug Approvals

The pharma industry and US FDA will reflect on a record breaking 2018 for drug approvals. The Center for Drug Evaluation and Research (CDER) approved 59 new drugs last year which is a significant increase from previous years (FIG. 1; area plots). In the last 10 years, the FDA has approved 271 novel drugs and 85 biologics (FIG. 1, line plots). The new approvals for 2018 includes 42 new molecular entities and 17 new biologics. Small molecules dominate the list contributing to 64% of the approved drugs, while antibodies represent another 20%. There was a 40% increase in approvals of cancer therapies as compared to 2017. Increased approval trends were observed towards the end of the year with the last quarters accounting for more than 70% of the approved drugs. Oral dosage forms, such as tablets and capsules, accounted for greater than 80% of approved drugs (FIG. 2).

Continue reading

2018 Year In Review: Patent Publication Trends

We have published the second volume of our newsletter which gives an insight into the patent publication trends of the past year. The classification has been done based on countries, companies, and more. The graphical representation of the various statistical values aim to provide an overview of how the patenting scenario has changed and the technologies which show promise for patents.

Continue reading

Hot Topics in Tech | December 2018 Newsletter

In the December issue of the “Hot Topics in Tech” newsletter series, we take a glance at how mobile devices have transformed healthcare and became a crucial component in the medical field.

Continue reading

Hot Topics in Tech | November 2018 Newsletter

In this issue of the "Hot Topics in Tech" series, we provide a brief overview of the patent filing activity around implantable non-energy based devices for hypertension treatment and management. We have also presented the top technologies within this domain, leading assignees, and market information.

Continue reading

Hot Topics in Tech | October 2018 Newsletter | Maxval

This article provides a brief overview of the role of the autonomous nervous system in managing hypertension and describes various techniques related to neurostimulation. Patents revealing various energy-based techniques for neurostimulation, and devices related thereto which are available in the market are also presented.

Continue reading

Hot Topics in Tech | September 2018 Newsletter | Maxval

This issue covers cardiovascular diseases and discloses the technological categories and products related to the use of renal denervation approach for managing hypertension. It also talks about the three main categories of Artificial Intelligence namely Artificial Narrow Intelligence (ANI), Artificial General Intelligence (AGI), and Artificial Super Intelligence (ASI). They influence human life in the form of automated cars, virtual assistants, image recognition software, robotics, games, life science and so on. Read more on this report.

Continue reading

Hot Topics in Tech | August 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and blockchain technology industries. We have highlighted Illumina’s Q2 results and provided some
insights about the company alongwith a quick run-through of the firm's recent collaborations in China. Illumina reported a revenue of $830 million in Q2 which is a 25% increase compared to $662 million in the same quarter of 2017. Illumina’s biggest advantage over its competitors lies in its technology diversification.

Continue reading

Hot Topics in Tech | June 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and cloud-tech industries. We have talked about the FDA's approval of tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.), a CD19-directed genetically modified autologous T-cell immunotherapy, to include treatment of patients with relapsed or refractory large B-cell lymphoma. Tisagenlecleucel is the only CAR T-cell therapy to receive FDA approval for two distinct indications. The report includes a chart of major commercial players in the CAR T-cell space and a Year-on-Year trend on the number of patents and patent applications from 2012 to 2018.

Continue reading

Recent advances in Life Sciences | May 2018 Newsletter | MaxVal

The article presents a base editing approach to expand the scope and efficiency of CRISPR mediated genome editing.

Continue reading

Recent advances in Diabetes Management | April 2018 Newsletter | MaxVal

The article addresses Medtronic’s recent FDA approval of the Guardian™ Connect Continuous Glucose Monitoring (CGM) system. A brief overview of all the clinical studies related to CGM has been presented.

Continue reading